M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy

被引：1
|
作者：
Lockmer, Sandra [1 ,2 ]
Ren, Weicheng [3 ]
Ostenstad, Bjorn [4 ]
Brodtkorb, Marianne [5 ]
Wahlin, Bjorn E. [6 ,7 ,8 ]
Pan-Hammarstrom, Qiang [9 ]
Kimby, Eva [10 ]
机构：
[1] Karolinska Inst, Dept Internal Med, Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden
[3] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden
[4] Oslo Univ Hosp, Oslo, Norway
[5] Oslo Univ Hosp, Dept Oncol, Oslo, Norway
[6] Karolinska Univ Hosp, Dept Hematol, Solna, Sweden
[7] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden
[8] Karolinska Univ Hosp, Stockholm, Sweden
[9] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden
[10] Karolinska Inst, Hematol, Stockholm, Sweden
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-117949
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4154
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
    Gwladys Claustre
    Coralie Boulanger
    Frédéric Maloisel
    Nelly Etienne-Selloum
    Luc-Matthieu Fornecker
    Eric Durot
    Florian Slimano
    Véronique Graff
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1883 - 1893
  • [32] Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival
    Turturro, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (07) : 959 - 965
  • [33] Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial
    Kahl, Brad S.
    Burke, John M.
    van der Jagt, Richard
    Chang, Julie
    Wood, Peter
    Hawkins, Tim
    MacDonald, David
    Trotman, Judith
    Simpson, David
    Kolibaba, Kathryn S.
    Issa, Samar
    Hallman, Doreen
    Chen, Ling
    Flinn, Ian W.
    BLOOD, 2017, 130
  • [34] Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma
    Claustre, Gwladys
    Boulanger, Coralie
    Maloisel, Frederic
    Etienne-Selloum, Nelly
    Fornecker, Luc-Matthieu
    Durot, Eric
    Slimano, Florian
    Graff, Veronique
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) : 1883 - 1893
  • [35] Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Folio First-Line Therapy in Patients with Follicular Lymphoma
    Chen, Qiushi
    Ayer, Turgay
    Nastoupil, Loretta J.
    Rose, Adam C.
    Flowers, Christopher R.
    VALUE IN HEALTH, 2015, 18 (02) : 189 - 197
  • [36] Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma: FOXO1 Mutational Status May be a Predictive Marker of Early Progression and Long-Term Outcome
    Bantilan, Kurt S.
    Zelenetz, Andrew D.
    BLOOD, 2023, 142
  • [37] Choosing First-Line Therapy for Follicular Lymphoma (FL): A Decision Analysis
    Olin, Rebecca L.
    Kanetsky, Peter A.
    Ten Have, Thomas
    Nasta, Sunita Dwivedy
    Schuster, Stephen J.
    Andreadis, Charalambos
    BLOOD, 2008, 112 (11) : 250 - 251
  • [38] Determinants of the optimal first-line therapy for follicular lymphoma: A decision analysis
    Olin, Rebecca L.
    Kanetsky, Peter A.
    Ten Have, Thomas R.
    Nasta, Sunita D.
    Schuster, Stephen J.
    Andreadis, Charalambos
    AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (04) : 255 - 260
  • [39] PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN SPANISH PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA
    Rubio-Terres, C.
    Gomez-Codina, J.
    Rios, Herranz E.
    Castro, A. J.
    Varela, C.
    Ray, J. A.
    VALUE IN HEALTH, 2008, 11 (06) : A481 - A481
  • [40] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Eliazar Sabater
    Armando López-Guillermo
    Antonio Rueda
    Antonio Salar
    Itziar Oyagüez
    Juan Manuel Collar
    Applied Health Economics and Health Policy, 2016, 14 : 465 - 477
12345